Boulder’s OnKure goes public with merger; key drug trial underway
OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a merger that takes OnKure public and injects $65 million into the company as it moves through a key trial for its leading breast cancer drug candidate.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
Mosaic Biosciences Inc., a Boulder drug-discovery company that provides protein and antibody therapeutics research to…
-
Enliven Therapeutics finished the third quarter with $292 million in cash, which, the company said,…
